Company at a Glance
Pascal Biosciences Inc. is a preclinical-stage biopharmaceutical company developing innovative therapeutics to address unmet medical needs in cancer. Pascal was founded in 2013 in Vancouver, Canada based on discovery research at The University of British Columbia (UBC). To realize clinical benefit from the fruits of the ongoing basic discovery research at UBC, Pascal established a Research and Development subsidiary in Seattle, WA. This facility is led by biotech veterans with an average of 25 years of drug discovery and development experience. Our dedicated team is driven to advance novel therapeutics, including cannabinoid-based and targeted molecules to improve and extend cancer patients’ lives.
The company’s stock is publicly traded on the TSX: Venture Exchange under the symbol “PAS”, and on the Frankfurt Stock Exchange (FSE) under the symbol “6PB.F”.